Can you answer the following questions about
Rescriptor®?
What is the generic name? Any abbreviations?
What "class" antiretroviral is it and how does it work?
With food, without food or food doesn't matter?
Any side effects?
Why is
Rescriptor® infrequently used in
practice?
Any possible drug interactions?
What is a typical dose?
Any other significant counseling points?
Rescriptor ® (Delavirdine) is a non-nucleoside reverse transcriptase inhibitor
(NNRTI)
that inhibits viral replication.
Rescriptor ®
(Delavirdine)
is dosed as 400 mg tid.
Rescriptor
®
(Delavirdine) may be
taken with or without food, but
separate dosing from
antacids or Videx® (Didanosine) by 1 hour. Videx®
EC, the new enteric coated didanosine may
be given at the same time.
Side effects include rash,
elevated transaminase levels, and
headaches.
Rare cases of Stevens-Johnson Syndrome have been reported with the use of
NNRTIs.
Rescriptor ® (Delavirdine) is metabolized by cytochrome P450 and is an
inhibitor of
cytochrome P450 enzymes.
Due to the high dosage frequency of delavirdine and the availability of other
more potent and convenient NNRTIs, it is not used very frequently in
practice.
As with all antiretrovirals, adherence is
crucial. Non-adherence is a
frequent cause of drug failure and viral resistance, not only to
Delavirdine,
but to other NNRTIs as well.
